TABLE 2.

Susceptibility to cefixime and levofloxacin, and amino acid substitutions identified in PBP1, PBP2, and porin of the N. gonorrhoeae strains used in this study

GroupSubgroupaStrain no.MIC (μg/ml)Amino acid substitutions in:b
PBP1cPBP2dPorine
CefiximeLevofloxacin375A421L537Y696P1 to 500501A504F510A512N516A541H542G545G549A551P552P555K556I566I574AType120G121A
I (n = 10)aMSC022460.0080.008....None...............PIB..
aMSC022820.0080.03....None...............PIB..
aMSC02261, MSC022670.0160.008....None...............PIB..
aMSC022780.0160.03....None...............PIB..
bMSC022350.0080.008T.C.None.LV.G..........PIB..
bMSC022630.0080.06T.C.None.LV.G..........PIB..
cMSC02242, MSC022480.0080.004-0.008....None.LV.G.........NVPIADG
dMSC022790.030.25....NoneVLV.GN....VQVVNVPIBD.
II (n = 20)aMSC022750.031.P..None.LV.G..........PIBKD
bMSC022660.0081.P..None.LV.G.S........PIBKN
cMSC02243, MSC02255, MSC02264, MSC022700.038.P..None.LV.G....S.....PIBKD
cMSC022540.0316.P..None.LV.G....S.....PIBKD
dMSC022680.0081.P..None.LV.G.S......VNVPIBKD
dMSC022280.0164.P..None.LV.G.S......VNVPIBKD
dMSC022470.0164.P..None.LV.G.S......VNVPIBRD
dMSC022590.0168.P..None.LV.G.S......VNVPIBKD
dMSC022600.0168.P..None.LV.G.S......VNVPIBKD
dMSC022770.0164.P..None.LV.G.S......VNVPIBKD
dMSC022270.034.P..None.LV.G.S......VNVPIB..
dMSC022300.034.P..None.LV.G.S......VNVPIBKD
dMSC02258, MSC022720.038.P..None.LV.G.S......VNVPIBKD
dMSC022650.034.P..None.LV.G.S......VNVPIBKD
dMSC022710.034.P..None.LV.G.S......VNVPIBKD
dMSC022810.038.P..None.LV.G.S......VNVPIBKD
III (n = 28)aMSC022310.1232.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022380.122.P..Mosaic-1.LVY.N.ST.VQVVNVPIB..
aMSC022400.124.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022260.258.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022340.252.P..Mosaic-1.LVY.N.ST.VQVVNVPIB..
aMSC022370.254.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022410.252.P..Mosaic-1.LVY.N.ST.VQVVNVPIB..
aMSC02250, MSC022510.2516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022730.2516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022740.258.P..Mosaic-1.LVY.N.ST.VQVVNVPIBND
aMSC022800.2516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022830.254.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022320.516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC02233, MSC022570.516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
aMSC022360.516.P..Mosaic-1.LVY.N.ST.VQVVNVPIBKD
bMSC022520.2516.P.SMosaic-1.LVY.N.ST.VQVVNVPIBKD
bMSC022690.2516.P.SMosaic-1.LVY.N.ST.VQVVNVPIBKD
cMSC022250.254.P..Mosaic-2.LVY.N.ST.VQVVNVPIBKD
cMSC02229, MSC02239, MSC02253, MSC022760.251-2.P..Mosaic-2.LVY.N.ST.VQVVNVPIBKD
cMSC022620.252.P..Mosaic-2.LVY.N.ST.VQVVNVPIBKD
dMSC022440.254.P..Mosaic-3.LVY.N.ST.VQVVNVPIBND
eMSC022560.122.P..Mosaic-4VLV..N..T.VQVVNVPIBKD
eMSC022450.258.P..Mosaic-4VLV..N..T.VQVVNVPIBKD
  • a Groups were subdivided on the basis of the amino acid sequences of PBP1 and PBP2.

  • b Dots, identical amino acids.

  • c All of the mutations found in PBP1 are shown.

  • d All the mutations after position 501 in PBP2 are shown. Every substitution is presented in Fig. 2 for mosaic PBP2.

  • e Only the mutations at position 120 and 121 are shown for porin.